亚司匹林与克洛皮多格雷尔单一治疗在复杂的皮肤冠状动脉干预后超过1个月:STOPDAPT-3试验的预先指定子组分析
Takenori Domei1, Ko Yamamoto1, Masahiro Natsuaki2
1Department of Cardiology, Kokura Memorial Hospital, Kitakyushu 802-8555, Japan.
European heart journal. Cardiovascular pharmacotherapy
|January 25, 2025
概括
阿司匹林单一治疗显示,复杂的皮肤冠状动脉干预 (PCI) 后,与克洛皮多格雷尔单一治疗相比,心血管事件的风险较低. 无论PCI复杂性如何,阿司匹林和克洛皮多格雷尔单独治疗之间的出血风险都相似.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 通过皮肤冠状动脉干预 (PCI) 后,双重抗血小板治疗 (DAPT) 持续时间至关重要.
- 简短的DAPT随后单一治疗是一种新兴的策略.
- 在复杂的PCI后最佳单疗选择仍在调查中.
研究的目的:
- 为了比较阿司匹林单疗法与P2Y12抑制剂 (克洛皮多格雷尔) 单疗法,在经过复杂PCI的患者进行1个月的DAPT后.
- 为了评估心血管事件和出血风险在这个特定的患者小组.
主要方法:
- 对STOPDAPT-3试验的子组分析,重点关注复杂PCI患者.
- 随机比较1个月DAPT之后的阿司匹林与1个月DAPT之后的克洛皮多格雷尔.
- 副主终点:心血管事件和严重出血,在30天的里程碑时进行评估.
主要成果:
- 在复杂的PCI和心血管事件的治疗策略之间观察到显著的相互作用 (P=0.04).
- 在复杂的PCI患者中,阿司匹林单一治疗表明心血管事件的风险在数值上较低 (3.3%对5.2%).
- 无论PCI复杂性如何,阿司匹林和克洛皮多格雷尔单一治疗之间没有发现出血事件的显著差异.
结论:
- 在短期DAPT后复杂的PCI患者中,阿司匹林单疗可能比克洛皮多格雷尔单疗更受青,关于心血管事件.
- 在阿司匹林和克洛皮多格雷尔单一治疗之间做出选择不会显著影响复杂PCI患者的出血风险.
- 需要进一步的研究来证实这些发现,并优化复杂PCI后的抗血小板策略.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160
Anticoagulant Drugs: Low-Molecular-Weight Heparins
652
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
652
Peptic Ulcer Disease IV: Management
75
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
75


